SCOLR and Dr Reddy's enter licensing deal

SCOLR Pharma has entered into a collaboration and license agreement with India-headquartered Dr Reddy's Laboratories. The parties will pursue the development and commercialization of an undisclosed oral prescription drug with significant potential for the cardiopulmonary market utilizing SCOLR's CDT technology.

Under the terms of the deal, Dr Reddy's will be responsible for the development, manufacturing and marketing of the drug, with SCOLR doing likewise for the formulation and assisting with product scale-up activities. The accord provides double-digit participation in net profits for SCOLR after recovery of development and commercialization expenses associated with the potential product. Other financial terms of the agreement have not been disclosed.